Replies to post #210405 on Biotech Values

[willyw]

FWIW...in reviewing several EASL abstracts it still appears to me that OCA validation continues to be supported by several of the abstracts I've read.

I'm trying to get more up to speed on NASH. I haven't yet listened to any of the other pitches today at the NASH Investor Conference.

[DewDiligence]

ENTA—Addendum re EDP-305 (NASH) slides:

https://twitter.com/DewDiligence/status/849015583958085632

[DewDiligence]

Re: ENTA's EDP-305 vs ICPT's Ocaliva in preclinical models

Direct link to ENTA’s 4/4/17 Wainwright slides:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNTE3MzF8Q2hpbGRJRD02NjU2NDI=

Slides #14-21 and 23 show EDP-305's superiority to ICPT's Ocaliva (OCA) in three animal models and one cell model.